SANUWAVE Lifts Q2 Revenue Outlook to $9.6M-$9.8M, Topping Prior View
SNWV sits 50% above its 52-week low of $7.53.
Summary
SANUWAVE raised its Q2 revenue guidance to $9.6M-$9.8M, up from the $8.5M-$9.5M range provided on June 16. The new midpoint of $9.7M exceeds the prior midpoint of $9.0M by about 8%, signaling stronger-than-expected demand or recovery from the CMS reimbursement headwinds cited in the earlier cut. The company reported preliminary Q2 2026 revenue of $9.6–$9.8 million, above the high end of its revised guidance. This follows a Q1 where the company reported positive operating cash flow and a sharply reduced net loss. The upward revision suggests the business is stabilizing faster than management anticipated just a month ago. Q2 results will confirm whether this momentum is sustainable.
At the time of this announcement, SNWV was trading at $11.26 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $96.8M. The 52-week trading range was $7.53 to $46.59. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.